Delcath Systems, Inc. (DCTH)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Delcath Systems, Inc. (DCTH)
Go deeper and ask any question about DCTH
Company Performance
Current Price
as of Sep 13, 2024$9.54
P/E Ratio
N/A
Market Cap
$267.12M
Description
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in Queensbury, NY.
Metrics
Overview
- HQQueensbury, NY
- SectorHealth Technology
- IndustryMedical Specialties
- TickerDCTH
- Price$9.54-2.75%
Trading Information
- Market Cap$267.12M
- Float84.68%
- Average Daily Volume (1m)352,591
- Average Daily Volume (3m)283,613
- EPS-$2.55
Company
- Revenue$11.88M
- Rev Growth (1yr)1,468.89%
- Net Income-$13.74M
- Gross Margin80.44%
- EBITDA Margin-49.09%
- EBITDA-$3.81M
- EV$223.09M
- EV/Revenue18.78
- P/EN/A
- P/S22.78
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset